DETERMINE

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial)

DETERMINE is the first UK national precision medicine trial in rare cancers*, testing a range of therapies specifically targeting key genetic changes in cancer cells.

A non-randomised trial, DETERMINE will explore whether treatments approved for use in some cancer types can target identifiable genetic alterations in other types. And provide new treatments options for those who might not have any left.

Drugs which show promising results will be accelerated for Cancer Drug Fund (CDF) assessment and NHS approval.

Participation criteria briefly include:

• Any patient with histologically proven locally advanced or metastatic cancer (solid tumour or haematological malignancy) who has:
  • exhausted (or declined) standard-of-care treatment options.
  • or for whom no effective standard treatment is available.
  • and whose disease has progressed, or is refractory.
• Diagnosis of a rare cancer harbouring an actionable genomic alteration, or common cancer types with rare actionable genomic alterations, that have been identified using a validated sequencing technique and for which there is a relevant open treatment arm within the DETERMINE trial.

For full participation details, see: https://clinicaltrials.gov/study/NCT05722886

DETERMINE is open or about to open at more than 20 sites across the UK – follow the link for locations and contacts:  https://clinicaltrials.gov/study/NCT05722886

If you are interested in this trial, please speak to your consultant.  

* Rare is defined generally as incidence fewer than 6 cases in 100,000 patients, or common cancers with rare alterations